Atlas Venture Advisors’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Atlas Venture Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,872,115	Closed	-$51.6M	–	9
2021 Q2	$51.6M	Hold	1,872,115	–	–	5.35%	3
2021 Q1	$30.9M	Sell	1,872,115 -784,402	-30%	-$17.9M	5.7%	2
2020 Q4	$49M	Sell	2,656,517 -1,176,603	-31%	-$21.1M	10.98%	2
2020 Q3	$52.2M	Sell	3,833,120 -88,888	-2%	-$1.37M	8.78%	2
2020 Q2	$70.3M	Hold	3,922,008	–	–	17.93%	2
2020 Q1	$39.1M	Hold	3,922,008	–	–	52.94%	1
2019 Q4	$31.9M	Hold	3,922,008	–	–	48.23%	1
2019 Q3	$38.9M	Hold	3,922,008	–	–	12.06%	2
2019 Q2	$49.5M	Hold	3,922,008	–	–	20.5%	2
2019 Q1	$40M	Hold	3,922,008	–	–	20.18%	2
2018 Q4	$29.4M	Buy	+3,922,008	New	+$28.7M	15.53%	2

Atlas Venture Advisors's TBIO Position: Q3 2021 in Review

Atlas Venture Advisors sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 1,872,115 shares — an estimated $51.6M sold.

Atlas Venture Advisors first reported a position in TBIO in Q4 2018 and held it in 11 quarters. The position peaked at $70.3M in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Atlas Venture Advisors reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Atlas Venture Advisors sold 1,872,115 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $51.6M.
Atlas Venture Advisors first reported a position in Translate Bio, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
Atlas Venture Advisors's Translate Bio, Inc. Common Stock position peaked at $70.3M in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Atlas Venture Advisors's 13F filing for Q3 2021, filed 4 Nov 2021.